| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 259.9 | 161.7 |
| Profit before tax | 73.9 | 25.9 |
| Net income | 55.5 | 390.9 |
| EPS (diluted, $ a share) | $0.35 | $2.43 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | -85.8% |
|---|---|
| Revenue, year on year | +60.7% |
| Operating margin | 33.0% |
10-Q filed with the SEC, NASDAQ: TGTX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Tg Therapeutics, Inc.: key numbers
- Share price
- $62.76Close, Nov 16
- Market cap
- $9.49B
- Shares outstanding
- 151.15MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Tg Therapeutics, Inc.
All →Tg Therapeutics Financial Results
TG Therapeutics reported Q3 2026 total global revenue of $259.9 million, driven by $232.6 million in U.S. net product revenue for BRIUMVI. The company raised its full-year 2026 total revenue guidance to approximately $1 billion and highlighted positive Phase 3 data for a simplified BRIUMVI initiation regimen.
- Term
- Q3 2026
“With solid third-quarter performance and a strong fourth quarter anticipated, we are on track to exceed $1 billion in global revenue in 2026, less than four years after launching BRIUMVI.”
Michael S. Weiss, Chairman and Chief Executive Officer
“Our increased full-year revenue guidance reflects the continued strength of our commercial business, while the approximately $100 million of shares repurchased during the quarter underscores our confidence in TG's long-term value.”
Michael S. Weiss, Chairman and Chief Executive Officer